Alliance Global Partners lowered the firm’s price target on Talphera to $3.50 from $4.25 and keeps a Buy rating on the shares post the Q2 report. The firm cites the hold on the company’s PFS assets and the delays in the NEPHRO study for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH: